Examine This Report on Antidepressant agent 5
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo objectives ended up To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients,